Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Shares of Pfizer Inc. PFE shed 3.49% to $21.84 Tuesday, on what proved to be an all-around poor trading session for the stock ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends.

This signals substantial size and strong market recognition. Positive Revenue Trend: Examining Pfizer's financials over ... Analysts typically rate each stock once per quarter.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ...